CA2424656A1 - Composition et procede pour liquides injectables stables - Google Patents

Composition et procede pour liquides injectables stables Download PDF

Info

Publication number
CA2424656A1
CA2424656A1 CA002424656A CA2424656A CA2424656A1 CA 2424656 A1 CA2424656 A1 CA 2424656A1 CA 002424656 A CA002424656 A CA 002424656A CA 2424656 A CA2424656 A CA 2424656A CA 2424656 A1 CA2424656 A1 CA 2424656A1
Authority
CA
Canada
Prior art keywords
composition according
component
glass
microparticles
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002424656A
Other languages
English (en)
Other versions
CA2424656C (fr
Inventor
Bruce Joseph Roser
Arcadio Garcia De Castro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVA BIO-PHARMA TECHNOLOGIES Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2689856A priority Critical patent/CA2689856C/fr
Publication of CA2424656A1 publication Critical patent/CA2424656A1/fr
Application granted granted Critical
Publication of CA2424656C publication Critical patent/CA2424656C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition destinée à administrer un composé stable et bioactif à un sujet et comportant un premier et un second composant, le premier composant contenant des microparticules d'un verre de glucide ou un verre de phosphate contenant l'agent bioactif. Le verre de glucide ou de phosphate peut comporter un composé facilitant la formation du verre, et le second composant comporte au moins un perfluorocarbone liquide biocompatible, dans lequel le premier composant est insoluble et dispersé. Le perfluocarbone peut comporter un tensio-actif.
CA2424656A 2000-10-13 2000-10-13 Composition et procede pour liquides injectables stables Expired - Lifetime CA2424656C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2689856A CA2689856C (fr) 2000-10-13 2000-10-13 Composition et procede pour liquides injectables stables

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/028244 WO2002032402A1 (fr) 2000-10-13 2000-10-13 Composition et procede pour liquides injectables stables

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2689856A Division CA2689856C (fr) 2000-10-13 2000-10-13 Composition et procede pour liquides injectables stables

Publications (2)

Publication Number Publication Date
CA2424656A1 true CA2424656A1 (fr) 2002-04-25
CA2424656C CA2424656C (fr) 2010-03-23

Family

ID=21741883

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2689856A Expired - Lifetime CA2689856C (fr) 2000-10-13 2000-10-13 Composition et procede pour liquides injectables stables
CA2424656A Expired - Lifetime CA2424656C (fr) 2000-10-13 2000-10-13 Composition et procede pour liquides injectables stables

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2689856A Expired - Lifetime CA2689856C (fr) 2000-10-13 2000-10-13 Composition et procede pour liquides injectables stables

Country Status (12)

Country Link
EP (1) EP1328255A1 (fr)
JP (1) JP2004513093A (fr)
KR (1) KR20030096224A (fr)
CN (1) CN100339066C (fr)
AU (2) AU2001211986B2 (fr)
CA (2) CA2689856C (fr)
ES (1) ES2337252T3 (fr)
MX (1) MXPA03003236A (fr)
NO (1) NO20031706L (fr)
PL (1) PL360052A1 (fr)
PT (1) PT1452171E (fr)
WO (1) WO2002032402A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1559433A4 (fr) * 2002-10-22 2009-11-04 Dainippon Sumitomo Pharma Co Composition stabilisee
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
GB0408199D0 (en) * 2004-04-13 2004-05-19 Cambridge Biostability Ltd Liquids containing suspended sugar glass particles
WO2005099669A1 (fr) 2004-04-13 2005-10-27 Cambridge Biostability Limited Liquides contenant des particules de verre en suspension
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en) * 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US8946200B2 (en) 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
JP5301468B2 (ja) * 2008-01-18 2013-09-25 旭化成ファーマ株式会社 安定な医薬組成物
US8404850B2 (en) 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8722706B2 (en) 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2010146536A1 (fr) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension de particules comprenant un médicament
WO2011007327A2 (fr) 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension pour usage thérapeutique et dispositif d'administration de ladite suspension
ES2362525B8 (es) 2009-10-08 2013-01-03 Azurebio, S.L. Formulación de medicamentos en forma de agujas percutaneas penetrantes.
US9028873B2 (en) 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
CN106132717B (zh) 2014-03-24 2018-09-14 精工爱普生株式会社 带打印装置和带打印系统
CN106102724A (zh) * 2014-03-27 2016-11-09 诺华股份有限公司 用于吸入活性药物成分的经喷雾干燥的水包油包固体分散系

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78151B (fr) * 1982-04-05 1984-09-26 Alcon Lab Inc
US5518731A (en) * 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
AU3924193A (en) * 1992-03-19 1993-10-21 Allergan, Inc. Compositions comprising a drug delivery vehicle suspended in a nonaqueous fluorinated liquid
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
US6190701B1 (en) * 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids

Also Published As

Publication number Publication date
CN100339066C (zh) 2007-09-26
MXPA03003236A (es) 2004-12-03
PT1452171E (pt) 2010-03-08
NO20031706D0 (no) 2003-04-11
AU1198601A (en) 2002-04-29
CN1527699A (zh) 2004-09-08
AU2001211986B2 (en) 2007-04-26
KR20030096224A (ko) 2003-12-24
JP2004513093A (ja) 2004-04-30
CA2689856C (fr) 2013-09-24
CA2689856A1 (fr) 2002-04-25
PL360052A1 (en) 2004-09-06
NO20031706L (no) 2003-04-11
CA2424656C (fr) 2010-03-23
WO2002032402A1 (fr) 2002-04-25
EP1328255A1 (fr) 2003-07-23
ES2337252T3 (es) 2010-04-22

Similar Documents

Publication Publication Date Title
CA2424656A1 (fr) Composition et procede pour liquides injectables stables
US6190701B1 (en) Composition and method for stable injectable liquids
EP0909562B1 (fr) Produits pour injection contenant des analogues de lipides a et procede de preparation correspondant
WO2006067608A1 (fr) Formulations aqueuses a base de hyaluronate de sodium a usage parenteral
CA1117417A (fr) Immunoglobuline serique stabilisee
CA1115206A (fr) Methode de preparation d'injections d'urokinase
AU2001211986A1 (en) Composition and method for stable injectable liquids
CA2438108C (fr) Composition pharmaceutique et methode d'injection a liberation controlee connexe
JP2003507388A (ja) 凍結乾燥したケーキの安定化
CN116650425A (zh) 糖酯化合物或其盐在冷冻保护、冷冻干燥保护中的应用
CA1214102A (fr) Preparation pharmaceutique contenant de la fibronectine purifiee
Maa et al. Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization
RU2003113537A (ru) Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
EP1007102B1 (fr) Procede de preparation de milieux de contraste
AU2005203369B2 (en) Pharmaceutical liquid suspensions
JP4027881B2 (ja) 安定注射液用の組成物および方法
KR100743442B1 (ko) 약제적 액체 현탁액
CN100594937C (zh) 稳定的注射液组合物和方法
EP1449523A1 (fr) Composition et procédé pour liquides injectables stables
RU2259817C2 (ru) Композиция для доставки стабильных инъецируемых жидкостей и способ доставки
JP4326030B2 (ja) リピッドａ類縁体含有注射用製剤及びその製造方法
JPS6219531A (ja) 安定なヒト型アンギオテンシン製剤
NZ525026A (en) A two-component composition comprising particles of sugar glass and a biocompatible liquid perfluorocarbon
NZ538681A (en) A pharmaceutical composition comprising active biological ingredient carried by particles that form a stable suspension in a liquid indefinitely
KR20000022502A (ko) 리피드a 유사체함유 주사용 제제 및 그 제조방법

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201013